Проблема выявления пациентов с семейной гиперхолестеринемией

Проблема выявления пациентов с семейной гиперхолестеринемией

Автор: Курбанисмаилова Патимат Меджидовна, Попова Анна Борисовна, Драненко Наталья Юрьевна, Сергиенко Игорь Владимирович

Журнал: Клиническая практика @clinpractice

Рубрика: Обзоры

Статья в выпуске: 3 (31), 2017 года.

Бесплатный доступ

В обзоре представлены современные данные, касающиеся этиологии и эпидемиологии семейной гиперхолестеринемии (СГХС), алгоритмов выявления пациентов с СГХС с использованием клинических шкал, генетического тестирования, каскадного скрининга. Приведены актуальные тактики лечения семейной гиперхолестеринемии, в том числе у детей и беременных женщин.

Семейная гиперхолестеринемия, каскадный скрининг, генетическое тестирование

Короткий адрес: https://sciup.org/143164651

IDR: 143164651

Список литературы Проблема выявления пациентов с семейной гиперхолестеринемией

  • Müller C. Xanthomata, Hypercholesterolemia, Angina Pectoris. Acta Med Scand 1938; 95(S89): 75-84.
  • Khachadurian A.K. The inheritance of essential familial hypercholesterolemia. Am J Med 1964; 37(3): 402-407.
  • Fredrickson D.S., Lees R.S. Editorial: A System for Phenotyping Hyperlipoproteinemia. Circulation 1965; 31(3): 321-327.
  • Goldstein J.L., Brown M.S. Familial Hypercholesterolemia: Identification of a Defect in the Regulation of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Activity Associated with Overproduction of Cholesterol. Proceedings of the National Academy of Sciences 1973; 70(10): 2804-2808.
  • Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: современные аспекты патогенеза, диагностики и лечения. М. 2017.
  • Kontula K., Koivisto U.M., Koivisto P., et al. Molecular Genetics of Familial Hypercholesterolaemia: Common and Rare Mutations of the Low Density Lipoprotein Receptor Gene. Annals of Medicine 1992; 24(5): 363-367.
  • Seftel H.C., Baker S.G., Jenkins T., et al. Prevalence of familial hypercholesterolemia in Johannesburg Jews. American Journal of Medical Genetics 1989; 34(4): 545-547.
  • Benn M., Watts G.F., Tybjaerg-Hansen A., et al. Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. The Journalof Clinical Endocrinology & Metabolism 2012; 97(11): 3956-3964.
  • Pijlman A.H., Huijgen R., Verhagen S.N., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209(1): 189-194.
  • Vuorio A., Kuoppala J., Kovanen P.T., et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews: Wiley-Blackwell; 2014.
  • Versmissen J., Oosterveer D.M., Yazdanpanah M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337(nov11 1): a2423-a2423.
  • Аншелес А.А., Шульгин Д.Н., Соломяный В.В. и др. Сопоставление результатов нагрузочных проб, данных однофотонной эмиссионной компьютерной томографии миокарда и коронарографии у больных ишемической болезнью сердца. Кардиологический вестник 2012; VII(2): 10-16.
  • Аншелес А.А., Халикова Э.И., Рыжикова О.А. Способ количественной оценки нарушений перфузии миокарда по данным однофотонной эмиссионной компьютерной томографии. Медицинская физика 2016; 69(1): 46-53.
  • Сергиенко В.Б., Аншелес А.А. Томографические методы в оценке перфузии миокарда. Вестник рентгенологии и радиологии 2010; 3: 10-14.
  • Аншелес А.А., Сергиенко В.Б. Томографические методы диагностики при оценке перфузии миокарда у больных с ишемической болезнью сердца. Медицинская радиология и радиационная безопасность 2011; 56(3): 74-79.
  • Аншелес А.А., Мартиросян Л.А., Сергиенко И.В. и др. Новые подходы к количественной оценке начальных нарушений и неоднородности перфузии миокарда по данным однофотонной эмиссионной компьютерной томографии. Вестник рентгенологии и радиологии 2015; 5: 17-26.
  • Marks D., Thorogood M., Neil H.A.W., et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168(1): 1-14.
  • Umans-Eckenhausen M.A.W., Defesche J.C., Sijbrands E.J.G., et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. The Lancet 2001; 357(9251): 165-168.
  • Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72(2): 171-176.
  • Teramoto T., Sasaki J., Ishibashi S., et al. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan. JAT 2013; 20(6): 517-523.
  • Сафарова М.С., Сергиенко И.В., Ежов М.В. и др. Российская научно-исследовательская программа по своевременной диагностике и лечению больных семей-ной гиперхолестеринемией: обоснование и дизайн российского регистра семейной гиперхолестеринемии (РоСГХС). Атеросклероз и дислипидемии 2014; 3: 7-15.
  • Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology 2011; 5(3): 133-140.
  • Watts G.F.,Sullivan D.R.,PoplawskiN.,etal.Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements 2011; 12(2): 221-263.
  • Ghosh S.K., Majumder B., Dutta A. Tuberous Xanthoma as a Presenting Feature of Familial Homozygous Hypercholesterolemia with Aortic Regurgitation. J Pediatr 2015; 166(1): 198-198.e191.
  • Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия. Современные аспекты диагностики, профилактики и терапии. Кардиология 2009; 1: 76-83.
  • Humphries S.E., Norbury G., Leigh S., et al. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 2008; 19(4): 362-368.
  • Soutar A.K., Naoumova R.P. Mechanisms of Disease: genetic causes of familial hypercholesterolemia. Nature Clinical Practice Cardiovascular Medicine 2007; 4(4): 214-225.
  • Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478-3490.
  • Taylor A., Wang D., Patel K., et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2009; 77(6): 572-580.
  • Motazacker M.M., Pirruccello J., Huijgen R., et al. Advancesingeneticsshowtheneedforextendingscreening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J 2012; 33(11): 1360-1366.
  • Ahmad Z., Adams-Huet B., Chen C., et al. Low Prevalence of Mutations in Known Loci for Autosomal Dominant Hypercholesterolemia in a Multiethnic Patient Cohort. Circulation: Cardiovascular Genetics 2012; 5(6): 666-675.
  • Fahed A.C., Nemer G.M. Familial Hypercholesterolemia: The Lipids or the Genes? Nutrition & Metabolism 2011; 8(1): 23.
  • Seidah N.G. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies. CPD 2013; 19(17): 3161-3172.
  • Bell D.A., Pang J., Burrows S., et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis 2015; 239(1): 93-100.
  • Ademi Z., Watts G.F., Pang J., et al. Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia. Journal of Clinical Lipidology 2014; 8(4): 390-400.
  • Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009; 17(6): 720-721.
  • George R., Kovak K., Cox S.L. Aligning Policy to Promote Cascade Genetic Screening for Prevention and Early Diagnosis of Heritable Diseases. J Genet Couns 2015; 24(3): 388-399.
  • Daniels S.R., Gidding S.S., de Ferranti S.D. Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5(3): S30-S37.
  • van der Graaf A., Avis H.J., Kusters D.M., et al. Molecular Basis of Autosomal Dominant Hypercholesterolemia: Assessment in a Large Cohort of Hypercholesterolemic Children. Circulation 2011; 123(11): 1167-1173.
  • Wiegman A. Family History and Cardiovascular Risk in Familial Hypercholesterolemia: Data in More Than 1000 Children. Circulation 2003; 107(11): 1473-1478.
  • Kusters D.M., de Beaufort C., Widhalm K., et al. Paediatric screening for hypercholesterolaemia in Europe: Table 1. Archives of Disease in Childhood 2011; 97(3): 272-276.
  • McCrindle B.W. Familial hypercholesterolemia in children and adolescents. Curr Opin Lipidol 2012; 23(6): 525-531.
  • Descamps O.S., Tenoutasse S., Stephenne X., et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218(2): 272-280.
  • Braamskamp M.J.A.M., Kusters D.M., Avis H.J., et al. Long-Term Statin Treatment in Children with Familial Hypercholesterolemia: More Insight into Tolerability and Adherence. Pediatric Drugs 2015; 17(2): 159-166.
  • Avis H.J., Hutten B.A., Gagné C., et al. Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. J Am Coll Cardiol 2010; 55(11): 1121-1126.
  • Stein E.A. Statins and Children: Whom Do We Treat and When? Circulation 2007; 116(6): 594-595.
  • Vuorio A., Kuoppala J., Kovanen P.T., et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews: Wiley-Blackwell; 2010.
  • Rodenburg J., Vissers M.N., Wiegman A., et al. Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better. Circulation 2007; 116(6): 664-668.
  • Jansen A.C.M., Aalst-Cohen E.S., Tanck M.W., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256(6): 482-490.
  • Oosterveer D.M., Versmissen J., Schinkel A.F.L., et al. Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. Clinical Lipidology 2010; 5(2): 189-197.
  • McCrindle B.W., O'Neill M.B., Cullen-Dean G., et al. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: A randomized, crossover trial. J Pediatr 1997; 130(2): 266-273.
  • Tonstad S., Knudtzon J., Sivertsen M., etal. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996; 129(1): 42-49.
  • Perry C.M. Colesevelam. Pediatric Drugs 2010; 12(2): 133-140.
  • Goldberg A.C. Novel therapies and new targets of treatment for familial hypercholesterolemia. Journal of Clinical Lipidology 2010; 4(5): 350-356.
  • Hopkins P.N., Toth P.P., Ballantyne C.M., et al. Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5(3): S9-S17.
  • Ito M.K., McGowan M.P., Moriarty P.M. Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology 2011; 5(3): S38-S45.
  • Klingel R., Gohlen B., Schwarting A., et al. Differential Indication of Lipoprotein Apheresis During Pregnancy. Therapeutic Apheresis and Dialysis 2003; 7(3): 359-364.
  • Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci 2009; 16(5): 431-437.
  • De Assis S.M., Seguro A.C., Helou C.M. Effects of maternal hypercholesterolemia on pregnancy and development of offspring. Pediatr Nephrol 2003; 18(4): 328-334.
  • Thadhani R., Stampfer M.J., Hunter D.J., et al. High Body Mass Index and Hypercholesterolemia. Obstetrics & Gynecology 1999; 94(4): 543-550.
  • Hameed A.B., Tummala P.P., Goodwin T.M., et al. Unstable angina during pregnancy in two patients with premature coronary atherosclerosis and aortic stenosis in association with familial hypercholesterolemia. Am J Obstet Gynecol 2000; 182(5): 1152-1155.
  • Youngblom E., Knowles J.W. Familial Hypercholesterolemia. In: Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., et al., editors. GeneReviews(R). Seattle (WA)1993.
  • Harada-Shiba M., Arai H., Oikawa S., et al. Guidelines for the Management of Familial Hypercholesterolemia. JAT 2012; 19(12): 1043-1060.
  • Anedda S., Mura S., Marcello C., et al. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women. Transfusion and Apheresis Science 2011; 44(1): 21-24.
  • Beigel Y., Bar J., Cohen M., et al. Pregnancy outcome in familial homozygous hypercholesterolemic females treated with long-term plasma exchange. Acta Obstetricia et Gynecologica Scandinavica 1998; 77(6): 603-608.
  • Fahed A., Nassar A. Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis. Am J Perinatol Rep 2012; 02(01): 033-036.
  • Mabuchi H., Sakai Y., Watanabe A., et al. Normalization of low-density lipoprotein levels and disappearance of xanthomas during pregnancy in a woman with heterozygous familial hypercholesterolemia. Metabolism 1985; 34(4): 309-315.
  • Shiomi M., Ito T., Watanabe Y. Increase in hepatic low-density lipoprotein receptor activity during pregnancy in Watanabe heritable hyperlipidemic rabbits; an animal model for familial hypercholesterolemia. Biochimica et Biophysica Acta (BBA) -Lipids and Lipid Metabolism 1987; 917(1): 92-100.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp